The economic principle popularized by economist Arthur Laffer is straightforward: when governments tax an activity more heavily, they often discourage it. That principle deserves particular attention when the products being taxed are essential to diagnosing diseases, treating patients and extending human life. President Donald Trump’s tariffs on medical technology risk raising healthcare costs, disrupting international supply chains and discouraging innovation-not only in the United States, but potentially across the global healthcare system.
Trump has frequently emphasized the importance of lowering prices for American consumers. Tax reductions, deregulation and greater transparency can help advance that objective. Yet tariffs on medical equipment and components work in the opposite direction. They increase the cost of producing, importing and maintaining technologies that hospitals depend on, potentially shifting the financial burden onto patients, insurers and taxpayers.
Medical technology is a global industry
Modern medical technology is not manufactured within neat national boundaries. MRI scanners, advanced imaging systems, surgical robots, diagnostic instruments and life-support equipment often depend on components, specialized materials and engineering expertise sourced from several countries. A finished device assembled in one nation may rely on magnets, semiconductors, software and precision components manufactured elsewhere.
This international division of labor reflects the complexity of advanced manufacturing. A tariff imposed on one imported component can raise production costs throughout the supply chain. Manufacturers may absorb some of the expense, but they may also pass it on through higher prices, delay investment or reconsider where to manufacture their products.
The World Health Organization, World Intellectual Property Organization and World Trade Organization have jointly examined the relationship between trade policy, public health, medical innovation and access to essential technologies. Their research underscores the importance of considering these issues together rather than treating trade restrictions as an isolated economic instrument.
Why domestic production cannot replace imports overnight
Supporters of tariffs argue that higher import costs encourage companies to manufacture domestically, create jobs and reduce dependence on foreign suppliers. Strengthening domestic production can be a legitimate strategic objective, particularly for essential medical equipment. But the assumption that local factories can quickly replace sophisticated imports overlooks the realities of medical manufacturing.
Consider MRI systems, which require highly specialized superconducting magnets, and positron emission tomography (PET) scanners, which depend on complex imaging technology and access to radioactive tracers. The equipment and materials needed to operate these systems are not interchangeable commodities that manufacturers can readily source from new suppliers.
Regulatory requirements create another obstacle. Medical devices must meet rigorous safety and performance standards. Depending on the component and the proposed change, manufacturers may need extensive testing, documentation and regulatory review before introducing an alternative supplier. These procedures protect patients, but they also make rapid supply-chain substitution difficult.
Tariffs therefore can impose immediate costs while delivering domestic production benefits, if any, only after substantial investment and considerable time.
The burden falls disproportionately on patients
Higher equipment prices do not remain confined to manufacturers‘ balance sheets. Hospitals must finance equipment purchases, maintenance, replacement parts and upgrades. When these expenses rise, healthcare providers may increase charges, postpone purchases or redirect limited budgets away from other services.
The consequences can be especially serious in lower-income countries, where hospitals already struggle to obtain reliable diagnostic equipment and essential medical supplies. Import duties on advanced technology can make it harder to establish imaging services, expand cancer diagnosis and modernize healthcare facilities.
Even wealthier countries face difficult choices. Public health systems must balance equipment spending against staffing, medicines, preventive care and other priorities. Higher prices for imported technology can reduce the number of machines hospitals can afford, potentially lengthening waiting lists and delaying diagnoses.
The impact is not identical everywhere: exchange rates, local manufacturing capacity, procurement rules and public subsidies all influence final prices. Nevertheless, tariffs that increase the cost of essential inputs create an additional barrier to affordable care.
Innovation requires open markets and investment
Medical technology advances through international collaboration. Researchers, engineers, universities, hospitals and manufacturers exchange knowledge and develop products that incorporate expertise from different countries. Restricting access to components or raising the cost of specialized equipment can weaken these relationships and reduce the resources available for research and development.
The United States remains a major force in medical technology, with an established manufacturing base, skilled workers and substantial research capabilities. Industry estimates published by AdvaMed indicate that American medical technology manufacturing supports millions of direct and indirect jobs. These strengths provide a foundation for competitiveness; they do not necessarily demonstrate that broad tariffs are needed to preserve it.
A more effective industrial strategy would identify genuinely vulnerable supply chains, encourage investment in critical domestic capabilities and strengthen partnerships with reliable international suppliers. Targeted incentives, research funding, workforce training and carefully designed procurement policies can support resilience without indiscriminately increasing the cost of medical products.
Strategic independence without economic self-isolation
Governments have legitimate reasons to avoid excessive dependence on a single supplier or foreign production center. The COVID-19 pandemic demonstrated the dangers of concentrated supply chains, while geopolitical tensions have made access to essential technologies a national security concern.
But resilience does not require every country to manufacture every component. It requires diversified suppliers, adequate inventories, reliable trade relationships and sufficient domestic capacity to respond to emergencies. Building these capabilities is different from imposing broad tariffs on products that hospitals cannot easily replace.
The best approach combines strategic domestic investment with international cooperation. Governments can support local production where it is economically and medically justified while maintaining access to specialized foreign technologies that cannot be replicated quickly or affordably.
Put patients ahead of protectionism
Medical technology policy should ultimately be judged by whether it improves health outcomes, expands access and encourages innovation. Tariffs that raise equipment costs without a realistic, measurable path toward stronger domestic capacity risk achieving the opposite.
President Trump should reconsider broad tariffs on medical technology and its essential components, including exemptions for products that cannot readily be sourced domestically. Other governments should likewise resist trade measures that make life-saving equipment more expensive without delivering clear public-health benefits.
The objective should not be to eliminate domestic manufacturing or ignore legitimate security concerns. It should be to build stronger industries without sacrificing affordability, competition and scientific progress.
Medical technology is an international enterprise serving a universal human need. When trade policy makes essential equipment more expensive, the consequences extend beyond corporate profits and national trade balances. They reach hospital budgets, medical research and patients waiting for diagnosis or treatment.
A healthier global economy requires more innovation, stronger supply chains and wider access to medical advances-not unnecessary barriers that make them harder to obtain.
Jennifer Hicks is a columnist and political commentator writing on a large range of topics.